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ABSTRACT
Perinatal hypoxic ischaemic encephalopathy (HIE) has a high mortality rate with 
neuropsychological impairment. This study investigated the neuroprotective effects 
of argon against neonatal hypoxic-ischaemic brain injury.
In vitro cortical neuronal cell cultures derived from rat foetuses were subjected 
to an oxygen and glucose deprivation (OGD) challenge for 90 minutes and then 
exposed to 70% argon or nitrogen with 5% carbon dioxide and balanced with oxygen 
for 2 hours.
In vivo, seven-day-old rats were subjected to unilateral common carotid artery 
ligation followed by hypoxic (8% oxygen balanced with nitrogen) insult for 90 minutes. 
They were exposed to 70% argon or nitrogen balanced with oxygen for 2 hours. In 
vitro, argon treatment of cortical neuronal cultures resulted in a significant increase 
of p-mTOR and Nuclear factor (erythroid-derived 2)-like 2(Nrf2) and protection 
against OGD challenge. Inhibition of m-TOR through Rapamycin or Nrf2 through 
siRNA abolished argon-mediated cyto-protection. In vivo, argon exposure significantly 
enhanced Nrf2 and its down-stream effector NAD(P)H Dehydrogenase, Quinone 
1(NQO1) and superoxide dismutase 1(SOD1). Oxidative stress, neuroinflammation and 
neuronal cell death were significantly decreased and brain infarction was markedly 
reduced. Blocking PI-3K through wortmannin or ERK1/2 through U0126 attenuated 
argon-mediated neuroprotection.
These data provide a new molecular mechanism for the potential application of 
Argon as a neuroprotectant in HIE.
INTRODUCTION
Perinatal hypoxic-ischaemic encephalopathy (HIE) 
is one of the largest contributors to neonatal brain injury 
with subsequent poor developmental outcome [1]. It has 
been shown that between 20-50% of asphyxiated infants 
die in the neonatal period, with 25% of survivors suffering 
neuropsychological deficits such as cerebral palsy, 
learning disabilities or epilepsy [2]. The encephalopathy 
caused by the ischaemia is defined initially by the primary 
injury, and is exacerbated by further processes involving 
apoptosis leading to brain damage [3]. The outcome of 
a hypoxic ischaemic episode is influenced by several 
factors such as the duration and severity of insult to the 
brain, gestational age, presence of seizures and associated 
infectious, metabolic and traumatic problems [2]. Given 
the incidence rate and huge impact on families, including 
the need for long-term multi-disciplinary care [4], 
prevention strategies are continually searched for [5].
Previous treatment for HIE included drugs that 
reduced cerebral odema such as osmotic diuretics [5]. 
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Current avenues for neuroprotection involve hypothermia 
[6], including total body cooling [7], with erythropoietin 
therapy also investigated [8]. However, treatments are 
far from optimal, therefore there is much scope for the 
discovery of novel strategies for HIE.
Reactive oxygen species (ROS) have been 
implicated to play a key role in the pathogenesis of HIE 
and induces cell death via oxidation of membrane lipids 
and proteins [9]. Nuclear factor (erythroid-derived 2) factor 
2 (Nrf2) mediates cellular protection against oxidative 
stress [10] and has become the focus of new neuro-
protective strategy. Under oxidative stress, Nrf2 proteins 
translocate into the nucleus. Nrf2 binds to antioxidant 
response elements (AREs) of DNA, and stimulates 
transcription of antioxidant proteins. These include 
gluthatione S-transferases (GSTs) and NAD(P)H: quinone 
oxidoreductase 1 (NQO1)[11]. Phosphatidylinositol 
3-kinase (PI3K)/Akt pathway (PI3K/Akt pathway) has 
been shown to regulate the Nrf-2 pathway [12].
Xenon, a noble gas, is a neuroprotectant 
with no known toxicity, has rapid onset and few 
side effects unlike other inhaled gases [13]. Its use 
is currently limited due to expense [3]. Recently, 
another noble gas, argon, has also been shown to have 
neuroprotective effects [8, 14]. In an in vitro model, it 
has been demonstrated that argon is neuroprotective in 
organotypic hippocampal cultures after oxygen glucose 
deprivation [15]. In addition, argon was protective 
against hypoxic injury and injury caused by cisplatin 
and gentamicin in rat cochlear cultures [16]. In an in 
vivo study, normobaric argon increased the survival 
rates of rats exposed to changing degrees of hypoxia 
[17]. The aim of this study was to investigate whether 
argon affects neuronal cell death and inflammation 
after hypoxic-ischaemic insult both in vitro to oxygen 
glucose deprivation induced injury and  in a rat model 
of neonatal asphyxia. In addition, the underlying 
molecular mechanisms including the role of Nrf2 were 
also explored.
RESULTS
Argon exposure induced up-regulation of PI-3K, 
Erk1/2 and p-mTOR in the cultured rat cortical 
neurons
To assess the role of PI3K/Akt pathway and MAPK 
pathway in cultured neurons following exposure to 
argon, the change in the expression of PI3K, ERK1/2 and 
p-mTOR were firstly assessed through immunofluorescent 
staining. The immunofluorescent intensity of PI3K, 
Erk1/2 and p-mTOR was markedly enhanced when the 
cells were exposed to argon (Figure 1A-1F). Enhanced 
expression was also observed in argon treated neuronal 
cell challenged with OGD (Figure 1A-1F).
Argon reduced neuronal injury induced by OGD 
in vitro through enhanced Nrf2 expression
OGD-induced injury provokes neuronal death 
through oxidative stress [18]. The nuclear factor 
erythroid 2-related factor 2 (Nrf2) is a critical regulator 
of cellular resistance to oxidants [11]. Studies have 
shown that activation of PI-3K pathway or ERK1/2 
pathway leads to enhanced production of Nrf2 through 
p-mTOR [19]. Increased expression and translocation 
of Nrf2 into nuclei were also observed after argon 
exposure (Figure 2A and 2B), indicating activation of 
the antioxidant system. Indeed, expression of its down-
stream effector NAD(P)H dehydrogenase (quinone 1) 
(NQO-1), which acts as a superoxide scavenger [20], 
was augmented during OGD challenge (Figure 2E and 
2F). 4 hours after treatment, production of ROS was 
assessed by flow cytometry (Figure 2C and 2D). Argon 
treatment significantly reduced production of ROS after 
OGD challenge (Figure 2C and 2D), and consequently, 
the expression of cleaved caspase-3 was decreased 
(p<0.05, argon vs N2), which indicated enhanced cell 
survival through OGD challenge after argon treatment 
(Figure 2G and 2H). The external morphology of 
neurons remained relatively unaltered 4 hours after 
OGD (Figure 2G and 2H). The neuronal cell viability 
was assessed by MTT assay at 24 hours after OGD 
exposure. Argon significantly increased the cell viability 
in OGD-exposed neurons (P<0.05, argon vs N2) (Figure 
2I). These results in combination give strong evidence 
that argon treatment conferred protection against OGD-
challenged neurons.
Inhibition of m-TOR and Nrf2 abolished argon-
mediated cyto-protection in cultured rat cortical 
neurons
Upon investigating whether argon-associated 
neuroprotection was mediated through p-mTOR and 
Nrf2, we demonstrated a reinstatement of cleaved 
caspase-3 expression of OGD-induced neurons when 
m-TOR inhibitor rapamycin was applied. Likewise, 
when neuronal cells transfected with Nrf2 siRNA were 
subjected to OGD, the increase was inhibited significantly 
(Figure 3A, 3B, 3E and 3F). The cultures without 
inhibitors showed extensive neuronal processes whereas 
those treated with inhibitors did not after OGD challenge 
(Figure 3A). The suppression of ROS production was 
attenuated by either Nrf2 siRNA or rapamycin (Figure 
3C and 3D). Consequently, cell survival after OGD 
challenge was significantly lower after Nrf2 or p-m-
TOR was blocked (Figure 3G). These results support 
the hypothesis that p-mTOR and Nrf2 regulate argon-
associated neuroprotection and mediate the resistance 
against oxidative stress in rat cortical neurons.
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Argon treatment enhanced expression of anti-
oxidant enzymes in rat cortex with hypoxic-
ischemia injury
In parallel with in vitro observation, 
immunofluorescence analysis demonstrated that 
p-mTOR, Nrf2 and its downstream effectors NAD(P)
H dehydrogenase (quinone 1) (NQO1) and superoxide 
dismutase 1(SOD1) protein expression levels were also 
increased considerably in hypoxic-ischaemia rat brain 
cortex after argon treatment, compared with those with 
nitrogen treatment (Figure 4A-4H). Meanwhile, the 
content of MDA in ischaemic cortical tissue was detected 
to examine the oxidative response at 24 hours after HI. 
MDA levels in hypoxic neurons were also reduced after 
argon treatment (Figure 4I). When argon was administered 
after hypoxia, it significantly increased the levels of GSH, 
reduced levels of GSSG in the developing brain after 24 
hours, the overall GSH-GSSG ratio was also increased by 
this treatment (Figure 4J-4L).
Argon reduced neuronal cell death and neuro-
inflammation in rat cortex after hypoxic-
ischaemia
To investigate whether argon was able to reduce 
neuronal cell death, cell morphology was assessed 24 
hours after HI. Overall increased numbers of healthy 
Figure 1: Enhanced expression of PI-3K, ERK1/2 and p-mTOR in cultured cortical neuronal cells after argon 
exposure. Rat neuronal cell culture was exposed to argon gas (70% Ar and 5% CO2 balanced with O2) or nitrogen gas (70% N2 and 5% 
CO2 balanced with O2) for 2 hours and then room air for 24 hours. For the OGD experiment, rat cortical neuronal cell culture were given 
oxygen glucose deprivation (OGD) for 90 minutes and then exposed to argon gas (70% Ar and 5% CO2 balanced with O2) or nitrogen gas 
(70% N2 and 5% CO2 balanced with O2), for 2 hours and then room air for 24 hours. A. Dual immunolabelling of α-Tubulin (Tu, green 
fluorescence) and p-mTOR (red fluorescence) B. Fluorescent intensity of p-mTOR at 4 hours after gas exposure. C. Dual immunolabelling 
of α-Tubulin (Tu, green fluorescence) and Erk1/2 (red fluorescence) D. Fluorescent intensity of Erk1/2 at 4 hours after gas exposure. E. 
Dual immunolabelling of α-Tubulin (Tu, green fluorescence) and PI-3K (red fluorescence) F. Fluorescent intensity of PI3K at 4 hours after 
gas exposure. Cell nuclei were counter-stained with DAPI (blue). Data are Mean ± SD. n = 8. *p<0.05 and **p<0.01 and ***p<0.001, scale 
bar: 50μm. NC: naïve control.
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cells were observed in the argon treatment group (Figure 
5A and 5B). Consistent with this observation, there was 
a significant reduction in the number of TUNEL+ cells 
between the nitrogen treated group and the argon treated 
groups 6 hours after the brain received HI injury (Figure 
5C and 5D), demonstrating that argon was able to reduce 
cell death. Cortical tissue inflammatory cytokines, such as 
TNF-α and IL-6 were reduced after argon exposure, which 
indicated that neuro-inflammation was attenuated by the 
treatment (Figure 5E and 5F). The long-term protective 
profile of argon treatment was explored. Extensive lesions 
developed in the cortex in N2 plus hypoxia treated groups 
(Figure 5G). Argon treatment significantly reduced 
infarction volume, when compared with nitrogen control 
(Figure 5G and 5H). The pathological change by the 
argon treatment correlated positively with rat body weight 
(Figure 5I), with argon exposure associated with increased 
body weight, when compared with nitrogen control.
Inhibition of ERK1/2 and PI-3K attenuated the 
argon-mediated neuroprotection
To determine which pathway argon bought about 
its neuroprotective effects, wortmannin, a specific PI3K 
inhibitor and U0126, a specific ERK1/2 inhibitor were 
utilised. Inhibition of PI-3K and ERK1/2 activities 
blocked the up-regulation of Nrf2 (Figure 6A) and 
the neuroprotective effects of argon (Figure 6B-6G). 
This provides further support that PI-3K and ERK1/2 
are positive regulators of the Nrf2 pathway and its 
neuroprotective effects.
Figure 2: Effect of argon exposure on cortical neuronal cell death after oxygen glucose deprivation (OGD). Rat neuronal 
cell culture were exposed to argon gas (70% Ar and 5% CO2 balanced with O2) or nitrogen gas (70% N2 and 5% CO2 balanced with O2) for 
2 hours and then room air for 24 hours. For the OGD experiment, rat cortical neuronal cell cultures were given OGD for 90 minutes and 
then exposed to argon gas (70% Ar and 5% CO2 balanced with O2) or nitrogen gas (70% N2 and 5% CO2 balanced with O2), 2 hours and then 
room air for 24 hours. A. Dual immunolabelling of α-Tubulin (Tu, green fluorescence) and Nrf2 (red fluorescence) B. Fluorescent intensity 
of Nrf2 at 4 hours after gas exposure. Cellular ROS (O.- stained with DHE) and (H2O2 stained with DCF) were assessed by C. Flow 
cytometry and D. Fluorescent microscopy. E. Dual immunelabelling of α-Tubulin (green fluorescence) and NQO-1 (red fluorescence) F. 
Fluorescence intensity of NQO-1 at 4 hours after gas exposure. G. Dual immunelabelling of α-Tubulin (green fluorescence) and caspase-3 
(red fluorescence) H. Fluorescent intensity of caspase-3 at 4 hours after gas exposure. I. Cell viability assessed by MTT assay. Data is 
expressed as Mean ±SD. (n=8, **p<0.01 and ***p<0.001). Scale bar: 50μm. NC: naïve control, IC: injury control. Hy:Hypothermia.
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DISCUSSION
The present studies were undertaken to test 
the hypothesis that argon exposure would initiate the 
protective response against HI brain injury in neonatal 
rats. The transcription factor Nrf2 was found to play a 
pivotal role in mediating the neuroprotective effects of 
argon.
It is only relatively recently that the neuroprotective 
action of argon has been recognised [21]. Furthermore 
it has been shown that argon given after excitotoxic or 
ischaemic insult reduces neuronal cell injury [22]. In this 
study, argon exposure induced enhanced expression and 
nuclear translocation of Nrf2 in cultured cortical neuronal 
cells. In addition, production of reactive oxygen species 
(ROS) and caspase-3 activation were markedly decreased 
when argon treatment was given to neurons exposed to 
OGD. Parallel to in vitro observation, our in vivo study has 
also demonstrated that argon exposure to neonatal rats with 
hypoxic-ischaemic insults decreased the level of MDA 
product, increased the down-stream effector expression 
of NAD(P)H dehydrogenase [quinone] 1(NQO1) and 
superoxide dismutase 1(SOD-1). Consequently, neuronal 
cell death was suppressed and infarct volume was reduced 
(summarised in Figure 7).
Our study demonstrates, for the first time, that the 
neuroprotective mechanisms of argon involve activation 
of the transcription factor NF-E2-related factor 2 (Nrf2), 
which is considered to be a mediator of organoprotection 
by up-regulating the expression of many antioxidant 
enzymes under oxidative stress [23]. Nrf2 is a basic leucine 
zipper transcription factor that binds and activates the 
Figure 3: Inhibition of Nrf2 or p-mTOR attenuated the cytoprotective effects conferred by argon in cortical neuronal 
cells after OGD deprivation. Rat cortical neuronal cells transfected with negative control scramble siRNA or Nrf2 siRNA for 6 
hours, prior to OGD treatment, or were treated with p-mTOR inhibitor rapamycin, after OGD treatment. Rat cortical neuronal cell culture 
were given OGD for 90 minutes and then exposed to argon gas (70% Ar and 5% CO2 balanced with O2) or nitrogen gas (70% N2 and 5% 
CO2 balanced with O2) for 24 hours. A. Dual immunolabelling of α-Tubulin (green fluorescence) and Nrf2 (red fluorescence), B. Dual 
immunelabelling of α-Tubulin (green fluorescence) and caspase-3 (red fluorescence). C. Cellular ROS (O.-) and D. (H2O2) are assessed by 
flow cytometry, E. Fluorescent intensity of Nrf2 at 4 hours after gas exposure. F. Fluorescent intensity of cleaved caspase-3 at 4 hour after 
gas exposure. G. Cell viability assessed by MTT assay. Data is expressed as Mean ±SD. (n=8, *p<0.05 and ***p<0.001). Scale bar: 50μm. 
NC: naïve control, OGD: oxygen glucose deprivation. Ve: Vehicle, Rap: rapamycin, SSi: scramble siRNA, NSi: Nrf2 siRNA.
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transcription of antioxidant response element (ARE) [19]. 
Under normal physiological conditions, Nrf2 is bound to 
Kelch-like ECH-associated protein 1 (Keap1), leading 
Nrf2 to ubiquitination and proteosomal degradation [24]. 
However, under oxidative stress, Keap 1 repression of 
Nrf2 is inhibited, Nrf2 protein is then translocated into 
the nucleus and activates its target genes [25]. Activation 
of Nrf2 has been shown to be mediated through ERK1/2 
pathway [26] and PI3k/Akt [27]. The antioxidant genes 
controlled by Nrf2, include heme oxygenase-1 (HO-1), 
glutathione S-transferases (GSTs) and NAD(P)H quinone 
oxidoreductase, which scavenge reactive oxygen species 
(ROS) and prevent damage by oxidative stress [11]. 
Recent studies show that Nrf2 mediates protection against 
neuronal cell death [28] and neuro-inflammation [29]. 
Consistent with these studies, we observed significant 
up-regulation of SOD-1 and NQO1 in neonatal rat brain 
cortex after HI, following treatment with argon.
Previous studies have demonstrated the 
neuro-protective nature of argon, Ulbrich et al [30] 
demonstrated argon conferred neuroprotection via an 
induction of an ERK with critical involvement of HO-1 
(heamoxiginase-1) in retinal ganglion cells after ischemia 
and reperfusion injuries. This is consistent with our study; 
since HO-1 regulates the anti-oxidative response against 
cell injury and it is involved in the regulation of the 
expression and activity of Nrf-2 [31].
Our study also explored the effect of argon 
exposure on PI3K, Erk1/2 and p-mTOR, which play 
key roles in many cellular processes such as cell 
proliferation. P13K activates Akt and then m-TOR 
[32]. It has been reported that xenon exposure activates 
the P13K/Akt pathway in neuronal cell cultures [33]. 
There is also cross talk from PI3K to activate ERK, a 
ubiquitous cell proliferation and survival enzyme [34, 
35]. Previously, it was demonstrated that argon markedly 
increased expression of ERK, in the microglial cell line, 
BV-2 and in neuronal and astroglial cell cultures [36]. 
In this study, PI-3K and ERK expression was increased 
at 4 hours after gas treatment. Potentially argon works 
Figure 4: Argon treatment activates anti-oxidative protein expression and reduced oxidative stress in brain cortex 
with hypoxic-ischaemia injury. Rats were given hypoxic ischaemia injury for 90 minutes and then exposed to argon gas (70% Ar 
balanced with 30% O2) or nitrogen gas (70% N2 balanced with 30% O2) for 2 hours and then room air for 24 hrs. In rat cortex, expression 
of A. p-mTOR (green fluorescence) B. Fluorescent intensity of p-mTOR at 4 hours after gas exposure. C. Nrf2 (green fluorescence) D. 
Fluorescent intensity of Nrf2 at 4 hours after gas exposure. E. NQO-1 (red fluorescence) F. Fluorescent intensity of NQO-1 at 4 hours after 
gas exposure. G. SOD-1 (red fluorescence) H. Fluorescent intensity of SOD-1 at 4 hours after gas exposure. Cell nuclei were counter-
stained with DAPI (blue). I. Cortical tissue MDA level. J. Cortical tissue GSH level, K. Cortical tissue GSSG level. L. Cortical tissue GSH 
to GSSG ratio. Data are means ± SD. n = 8. *p<0.05 and ***p<0.001, scale bar: 50μm. NC: naïve control, HI: hypoxic ischaemia injury.
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via PI-3K cell signalling cascade as well as ERK, and in 
addition could also act via crosstalk between P13K and 
ERK [34]. This is further supported by the use of PI-3K 
inhibitor wortmannin and ERK1/2 inhibitor U0126 to 
abolish argon-mediated neuroprotection.
Argon is safe and has no record of toxicity. In our 
study, argon exposure was effective in promoting neuronal 
survival after OGD and reducing experimental hypoxic-
ischemia injury in neonatal rats. Both argon and xenon 
have good blood brain barrier penetration [14], which 
means both have rapid onset. Given that argon is relatively 
inexpensive compared to xenon, if argon can be shown 
to be as neuroprotective as xenon, it could be a more 
economically viable treatment, making it promising for 
clinical use. Further studies should investigate whether 
other signalling pathways are also involved in the 
protective effects of argon. Taken together, this suggests 
that argon may be useful in treating ischaemic injury in 
humans.
Figure 5: Effect of argon on neuronal cell death and inflammation in brain cortex after hypoxic-ischaemia. Rats were 
given hypoxic ischaemic injury for 90 minutes and then exposed to argon gas (70% Ar balanced with 30% O2) or nitrogen gas (70% N2 
balanced with 30% O2) 2 hours and then room air for 24 hrs. A. Cresyl violet staining of brain cortex 24 hours after gas exposure. B. 
Number of healthy neuronal cells per x 20 field 24 hours after gas exposure (n = 8). C. Tunnel staining at 24 hours after gas exposure. D. 
Number of TUNEL positive neuronal cells per x 20 field 24 hours after gas exposure (n = 8). E. Neonatal rat brain cortex tissue TNF-α level 
24 hours after gas exposure (n = 8). F. Neonatal rat brain cortex tissue IL-6 level 24 hours after gas exposure (n = 8). G. Representative 
brain micrograph 28 days after experiments, stained by cresyl violet. H. Infarct volume 28 days after experiments (n = 10). I. Body weight 
of rats 28 days after experiments (n = 10). Data are means ± SD. *p<0.05 and ***p<0.001, scale bar: 50μm. NC: naïve control, HI: hypoxic 
ischaemia injury.
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Figure 6: PI-3K and ERK1/2 inhibitors abolished argon-mediated neuroprotection. Rats were given hypoxic ischaemic injury 
for 90 minutes and then exposed to argon gas (70% Ar balanced with 30% O2) or nitrogen gas (70% N2 balanced with 30% O2) for 2 hours 
and then room air for 24 hrs. PI3K-Akt inhibitor wortmannin and Erk1/2 inhibitor U0126 was administered after hypoxic-ischaemia injury. 
A. Nrf2 expression (green fluorescence) in cortex at 24 hours after gas treatment. B. Cresyl violet staining of brain cortex 24 hours after 
gas exposure. C. Tunnel staining at 24 hours after gas exposure. D. Number of healthy cells in brain cortex per x 20 field 24 hours after gas 
exposure. E. Number of TUNEL+ neuronal cells in brain cortex per x 20 field 24 hours after gas exposure. F. Representative brain micrograph 
28 days after experiments, stained by cresyl violet. G. Infarct volume 28 days after experiments. Data are means ± SD. n = 8. *p<0.05 and 
**p<0.01 and ***p<0.001, scale bar: 50μm. NC: naïve control, HI: hypoxic ischemic injury. Ve: vehicle. W: wortmannin, U: U0126.
Figure 7: Proposed molecular mechanism for argon-mediated neuroprotection. Argon exposure induced activation of PI-3K 
and ERK1/2 pathway, leading to up-regulation of p-mTOR and Nrf2. Expression of down-stream anti-oxidative effectors, such as NQO-1 
and SOD-1 was enhanced, leading to suppression of ROS production in brain cortex after hypoxic-ischaemia. Consequently, neuronal cell 
death and inflammation were inhibited and brain infarction volume was reduced.
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MATERIALS AND METHODS
Primary cortical neuronal cell culture
Cortical neuronal cells were derived from embryonic 
day 18 Sprague Dawley rat foeti. Cerebral cortices were 
dissected and trypsinised in 0.25% trypsin for 30 minutes 
at 37°C. Cells were filtered through a 40μm cell strainer 
to obtain a single cell suspension, and then resuspended 
in neurobasal media (Gibco, UK), supplemented with 
glutamine (25μl/10ml;Sigma Aldrich), B27 (200μl/10ml; 
Sigma Aldrich) and antibiotic antimycotic solution 
(penicillin 100U/ml, streptomycin sulphate 100μg/ml, 
amphotericin B 0.25μg/ml; Fischer Scientific, UK). Cells 
were cultured in a humidified incubator at 37°C with 5% 
CO2 for 7 days before experiments.
Gas exposure in vitro
For the argon experiments, solutions were prepared 
by bubbling pure gases (nitrogen or argon; Air Products, 
Crewe, United Kingdom) through fine sintered-glass bubblers 
in Drechsel bottles (Pegasus, Guelph, Canada) filled with 
culture medium. Cells were kept in purpose-built, airtight, 
temperature-controlled, cell-culture chambers. These were pre-
filled with the desired concentration of argon after the culture 
medium had been replaced by argon-bubbled medium. In the 
post-OGD period, cells were returned to a normoxic incubator 
containing nitrogen or argon (75% argon or nitrogen, and 5% 
carbon dioxide balanced with oxygen) for 24 hours at 37°C.
Oxygen glucose deprivation (OGD)
The OGD procedure has been described 
on previous protocols [37]. Briefly, Neurobasal 
media (Gibco, UK) was replaced with a sterile and 
deoxygenated balanced salt solution pre-warmed to 
37°C, pH 7.4 with ionic composition (NaCl 116mm, 
KCl 5.4mm, MgSO4 0.8mm, NaH2PO4 1.0mm, CaCl2 
1.8mm, NaHCO3 26mm, glucose 5mm). Before use, 
pure nitrogen or argon gas was bubbled through for 20 
minutes using Drechsel bottles to remove oxygen from 
the solution. After replacing the media, the cultures were 
incubated for 90 minutes in an airtight gas chamber filled 
with treatment gas excluding oxygen. For the nitrogen 
group, the cultures were exposed to 95% N2 and 5% CO2 
and for the argon group, cultures were exposed to 70% 
argon, 25% N2 and 5% CO2. After 90 minutes, the media 
was replaced with neurobasal media and was incubated 
again for a further 24 hours at 70% argon, 25% O2 and 
5% CO2 for the argon group and 70% N2, 25% O2 and 
5% CO2 for the nitrogen group.
Animals
7-day old Sprague-Dawley rat pups were purchased 
from Harlan UK and housed in the animal facilities in 
Chelsea and Westminster hospital campus, Imperial 
College London. All procedures were conducted in 
accordance with the United Kingdom Animals (Scientific 
Procedures) Act of 1986. All animal procedure are 
compliant with the ARRIVE guidelines for reporting 
animal experiments [38].
Rat hypoxic-ischaemic brain injury
An in vivo rat model of neonatal hypoxic-
ischaemia (HI) was used for this study. Right common 
carotid artery ligation was performed on 7-day-old 
Sprague-Dawley rats under surgical anaesthesia (5% 
isoflurane induction, 2% isoflurane maintenance), as 
previously described [39]. After 1 hour of recovery, pups 
were exposed to hypoxia (8% oxygen balanced with 
nitrogen) for 90 minutes in purpose-built multi-chambers 
[14] which was made up with six multi-chambers, one 
gas reservoir bag, and one gas monitor with a built in gas 
pump. The total volume of the system is approximately 
3.5 L. The system was flushed with more than four times 
of system volume of the mixed gases before the closed 
gas delivery circle system was established. Soda lime 
and silica gel (Merck, Leicestershire, UK) was used in 
the chambers to eliminate CO2 and H2O generated by 
animals. The concentration of oxygen was measured 
continuously by an in-line gas analyser (Air Products 
Model No. 439Xe, Surry, UK). Immediately after the 
hypoxic insult, the pups were randomly allocated to be 
exposed to either 70% argon or 70% N2 balanced with 
oxygen for 2 hours in the purpose-built, close-circuit 
delivery system mentioned above. The pups were 
sacrificed and their brains harvested day 1 or day 28 
after gas treatment.
Administration of wortmannin and U0126
Rats were given PI3K inhibitor wortmannin (16 
μg/kg) [40], and Erk1/2 inhibitor U0126 ((1,4-diamino-
2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene; 1 
nmol for 5μL; Cellsignalling, UK) through intra-cerebral 
injection [41] 30 min before hypoxic-ischaemic treatment.
TUNEL staining
24 hours after HI, the presence of dead cells in the 
frontal cortex was detected an ApopTag® Fluorescein In 
Situ Apoptosis Detection Kit (S7110, Millipore, Bedford, 
MA) according to manufacturer’s instructions.
In vitro Nrf2 siRNA transfection and PI3K, 
ERK1/2 and m-TOR inhibition
SiRNA targeting rat Nrf2 (sc-37030, SantaCruz, 
USA) was administered to cultured neurons in a dose 
of 20nM, scrambled siRNA served as negative control. 
Cells were incubated with siRNA for 6 hours at 37 °C 
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in humidified air containing 5 % CO2, after which they 
were removed and replaced with experimental medium 
followed by OGD treatment. Other cohort cultures were 
treated with m-TOR inhibitor rapamycin (50 nmol/l) or 
vehicle (Tocris, Abingdon, UK) for 30 minutes before 
OGD treatment.
in vitro cell viability
The viability of cells was assessed using a 
colorimetric MTT assay (Merck KGaA, Darmstadt, 
Germany).
Determination of reactive oxygen species (ROS) 
in vitro by flow cytometry
ROS production was monitored by the measurement 
of superoxide (O2·–) and hydrogen peroxide (H2O2) 
generation using the fluorescent dyes dihydroethidium 
(DHE) [42] and carboxy-dichlorodihydrofluorescein 
diacetate (carboxy-DCF-DA)[43]. Cells were incubated 
in DHE (2μM) and carboxy-DCFDA (2μM) for 30 
minutes at 37 °C in the dark. The cells were washed with 
phosphate-buffered saline (PBS). Immunofluorescence 
intensity was acquired and analysed using flow cytometry 
(FACSCalibur; Becton Dickinson, Sunnyvale, CA). Each 
assay included at least 10,000 gated events.
Immunohistochemistry
For in vitro fluorescence staining, cells were fixed 
in 4% paraformaldehyde. Cells were then incubated in 
10% normal donkey serum in PBS-Tween 20 and then 
incubated overnight with either rabbit anti-p-m-TOR 
(1:200, Cell Signaling, Massachusetts, USA), rabbit 
anti-Nrf2 (1:200, Abcam), rabbit anti- NQO1 (1:200, 
Abcam), rabbit anti- cleaved caspase-3 (1:200, Cell 
Signalling, Massachusetts, USA), or mouse anti-α-tubulin 
(1:200, Sigma-Aldrich), followed by incubation with 
secondary antibody for 1 hour. For dual fluorescence 
labelling, cell samples or brain sections were incubated 
with the first primary antibody overnight, followed by its 
ascribed secondary antibody and then the second primary 
antibody incubation with subsequent secondary antibody. 
For in vivo fluorescence staining, the pups were sacrificed 
and transcardially perfused with 4% paraformaldehyde 
in heparinised PBS. The brains were then removed and 
fixed with 4% paraformaldehyde in PBS. They were then 
dehydrated in a 30% sucrose solution overnight before 
cryosectioning into 25 μm slices. Coronal sections were 
harvested between approximately -2.5 mm and -3.7 mm 
from bregma (relative to the adult rat brain). The brain 
sections were blocked with 3% normal donkey serum 
(NDS) (Millipore, Massachusetts, USA) in PBS with 
0.1% Triton (PBS-T) added to the sections for 1 hour to 
block non-specific binding sites and to permeabilise the 
cell membrane. After blocking and permeabilisation, the 
sections were incubated overnight at room temperature 
with either rabbit anti-Nrf2 (1:200, Abcam, Cambridge, 
UK), rabbit anti-NQO1 (1:200, Abcam) or rabbit anti- 
SOD1 (1:200, Abcam) followed by rhodamine- or 
fluorescein isothiocyanate (FITC) conjugated secondary 
antibodies (Millipore, UK). The slides were counter-
stained with nuclear dye DAPI and mounted with 
Vectashield mounting medium (Vector Laboaratories). 
Ten fields at ×20 view were first photographed using an 
AxioCam digital camera (Zeiss, Welwyn Garden City, UK) 
mounted on an Olympus BX60 microscope (Olympus, 
Middlesex, UK) with Zeiss KS-300 software. Staining was 
quantified using ImageJ software (U.S. National Institutes 
of Health, Bethesda, MD, USA). Fluorescent intensity 
was calculated as percentage of the mean value for naïve 
controls.
Assessment of morphology of neurons through 
cresyl violet staining
Rats were anesthetised with sodium pentobarbital 
(100 mg/kg, intra-peritoneal) and perfused trans-
cardially with paraformaldehyde (4%) in phosphate 
buffer (0.1 M). The brains were removed and placed in 
4% paraformaldehyde in 0.1 mol/L phosphate buffer 
overnight. The brains were dehydrated and embedded 
in wax. Coronal sections of 5 mm were harvested at 
approximately -3.6 mm from the bregma relative to 
adult brain and then stained with 0.5% cresyl violet. The 
microphotograph was taken at 20× using a BX-60 light 
microscope (Olympus, Southall, UK) attached with a 
digital camera (Zeiss, Gottingen, Germany). The following 
morphologic criteria were used to analyse apoptotic or 
necrotic cell death in the cerebral cortex [44]. Necrotic or 
apoptotic cells were identified by dark-stained, shrunken 
nuclei that were spherically shaped with loss of nuclear 
membrane integrity. The total number of healthy cells that 
appeared in the cortex in cresyl violet staining slices were 
counted in a blinded manner and their mean value used 
for data analysis.
Assessment of brain infarction through cresyl 
violet staining
The coronal sections (5 mm) from rats that 
received 90 mins hypoxic insult were selected from 
each pup to match predefined brain regions relative to 
the bregma (+2 mm, +1 mm, 0 mm, -1 mm, -2 mm and 
5 mm) relative to adult brain. Once identified, each slice 
was photographed and the size (arbitrary unit) of the 
healthy matter of both hemispheres was calculated with 
data analysis software (ImageJ version 1.31; National 
Institutes of Health image software, Bethesda, MD) in a 
blinded manner. The infarction size was calculated with 
a formula of [(left hemisphere-right hemisphere)/ left 
hemisphere] (%). These data were used to plot curves 
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and the area under curve calculated to indicate the 
infarction volume (arbitrary unit).
Enzyme-linked immunosorbant assay (ELISA)
Rat brain TNF-α and IL-6 concentration was 
measured by ELISA (Rat TNF-α and IL-6 ELISA kits, 
Invitrogen, UK).
Assessment of malondialdehyde (MDA) level
The amount of lipid peroxide was measured as the 
production of MDA using MDA assay kit (Sigma-Aldrich, 
UK).
Determination of total glutathione (GSH and 
GSSG)
Total glutathione (GSH and GSSG) was measured 
in brain homogenates using glutathione assay kit (Sigma-
Aldrich, UK).
Statistical analysis
Data is presented as mean ± standard deviation 
(S.D). Comparison between treatment groups was 
analysed by one-way ANOVA followed by post hoc 
Student Newman–Keuls test (GraphPad Prism 5.0 
Software). Data with p values of <0.05 were considered 
statistically significant.
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